key: cord-0785880-uxv06hen authors: Amat-Santos, Ignacio J.; Santos-Martinez, Sandra; López-Otero, Diego; Nombela-Franco, Luis; Gutiérrez-Ibanes, Enrique; Del Valle, Raquel; Muñoz-García, Erika; Jiménez-Diaz, Víctor A.; Regueiro, Ander; González-Ferreiro, Rocío; Benito, Tomás; Sanmartin-Pena, Xoan Carlos; Catalá, Pablo; Rodríguez-Gabella, Tania; Delgado-Arana, Jose Raúl; Carrasco-Moraleja, Manuel; Ibañez, Borja; San Román, J. Alberto title: Ramipril in High Risk Patients with COVID-19 date: 2020-05-26 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2020.05.040 sha: 61b4af13832c359a89dd3f2fa734f68781c115d5 doc_id: 785880 cord_uid: uxv06hen Abstract Background The coronavirus disease 2019 (COVID-19) is caused by SARS-CoV2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2 (ACE-2). This interaction has been proposed as a potential risk factor in patients treated with RAAS-inhibitors. Objectives To analyze if RAAS-inhibitors modify the risk for COVID-19. Methods RASTAVI (NCT03201185) is an ongoing randomized clinical trial randomly allocating Ramipril or control after successful transcatheter aortic valve replacement at 14 centers is Spain. We performed a non-pre-specified interim analysis to evaluate its impact on COVID-19 risk in this vulnerable population. Results As in April 1st 2020, 102 patients (50 Ramipril and 52 controls) were included in the trial. Mean age was 82.3±6.1 years, 56.9% males. Median time of Ramipril treatment was 6 months [IQR:2.9-11.4]. Eleven patients (10.8%) have been diagnosed with COVID-19 (6 in control group and 5 receiving Ramipril, HR=1.150 [95%CI: 0.351-3.768]). The risk of COVID-19 was increased in older patients (p=0.019), those with atrial fibrillation (p=0.066), lower hematocrit (p=0.084), and more comorbidities according to Society of thoracic surgeons score (p=0.065). Admission and oxygen supply was required in 4.9% (2 patients in the Ramipril and 3 in control), and 4 of them died (two in each randomized group). A higher body mass index was the only factor increasing the mortality rate (p=0.039). Conclusions In a high risk population of old patients with cardiovascular disease, randomization to Ramipril had no impact in the incidence or severity of COVID-19. This analysis supports the maintenance of RAAS-inhibitor treatment during COVID-19 crisis. The coronavirus disease 2019 outbreak is caused by a new coronavirus (1) (2) (3) (4) , the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (5) (6) (7) (8) (9) . According to several authors, the virus internalizes the cell by binding its trimeric spike protein to the human receptor angiotensin-converting enzyme 2 (ACE2) (10) (11) (12) . Renin-angiotensin-aldosterone (RAAS) inhibition upregulates ACE2, which casts doubts on whether the administration of these drugs could predispose to or worsen the course of the disease (13) (14) (15) . With this background, some authors advice the discontinuation of RAAS blockers either with prophylactic purposes or, in infected patients, to avoid the evolution to SARS (16) . On the other hand, high ACE2 levels have been shown to protect the lung in SARS (17) , and small series suggest an absence of a deleterious effect in hypertensive patients taking RAAS-inhibitors (18) cases and of deaths per million in the world. The RASTAVI trial is investigating the effect of adding Ramipril to the standard care in patients successfully treated with percutaneous aortic valve in terms of ventricular remodeling as assessed by cardiac magnetic resonance (CMR) and in the major clinical outcomes (19, 20) . By 5th May 2020, 3,525,116 people all over the world have been infected by SARS-CoV2 (21) whereas thousands of patients worldwide are taking RAAS-inhibitors daily. In this scenario, we aimed to describe for the first time the impact of COVID -19 pandemic in high-risk patients from the RASTAVI trial randomly assigned to receive Ramipril or standard care. The RASTAVI Study is a national, multicenter, open-label and randomized 1:1 trial aiming to determine the effect of Ramipril on cardiac events, functional capacity and cardiac remodeling on patients with aortic stenosis successfully treated with transcatheter aortic valve replacement (TAVR). The first patient was included in 2018 March 26 th , and the study will continue recruiting until end 2021. Patients are randomized, after signing informed consent, between 1 and 5 days after TAVR procedure to receive either standard care or an initial dose of Ramipril (2.5 mg daily). Titration of the Ramipril is performed at each monitorization visit aiming full dose (10 mg daily) if tolerated. Patients included in the control group if their blood pressure is beyond recommended parameters (140/90 mm Hg) receive any medication to control it, except for RAAS-inhibitors (19) . All patients from the study were contacted by phone and a questionnaire was performed to determine the presence of symptoms (fever, cough, dyspnea, syncope, myalgia, or others) in the last 5 months, or contact with confirmed cases of the disease. Also, any admission in the last months was recorded as per protocol, and the clinical reports as well as any laboratory exam were gathered. Confirmation of the infection was performed through real time reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal sample and the test was performed as clinically indicated. Categorical variables are reported as number (percent) and continuous variables as mean (standard deviation) or median (25th to 75th interquartile range), depending on variable distribution. Comparisons between those developing COVID-19 and those who did not were performed in order to determine predisposing factors.. Amongst COVID-19 patients (n = 11), fever was the most frequent symptom (63.5%), followed by cough (54.5%), dyspnea (27.3%) and myalgia (9.1%). Five patients presented severe respiratory disease that required admission to a healthcare institution and specific treatment (lopinavir/ritonavir, hydroxychloroquine, azithromycin, and corticoids) as opposed to only symptomatic treatment in those who did not require hospitalization. Four of these five hospitalized patients (36.4% of the COVID-19 cases) died as a consequence of bilateral pneumonia with severe acute respiratory distress. The specific characteristics of each one of the four patients who died are described in detail in Table 2 In the beginning of the COVID-19 pandemic certain publications called for the discontinuation of RAAS-inhibitors, both to potentially -we must not miss the hypothetical nuance -prevent the disease and to improve the prognosis in patients already suffering or with suspected COVID-19 (16, (22) (23) (24) (25) . This call for caution has prevailed in the medical community and the media despite the rise of discordant voices defending alternative hypothesis (26) and has led the American College of Cardiology to request for urgent research to clarify this aspect (27). Hypertension has been described as one of the most common coexisting conditions in patients admitted in hospital due to COVID-19 (28) , probably as a result of its higher prevalence in older patients. Often, this cardiovascular condition is treated with RAAS-inhibitors, which explains the great clinical relevance of clarifying the potential role of these drugs in COVID-19 pandemic. The main findings of our study suggest that: 1/ Age, but not hypertension, seems to be the only factor significantly associated with risk for developing the COVID-19 in this comorbid population. 2/ More than 10% of the patients developed the COVID-19 and one-third of them died, but the use of RAAS-inhibitors was neither associated with risk for the clinically symptomatic infection nor with poorer outcomes in the course of the disease. 3/ Patients who died due to the infection presented a higher body mass index as unique and characteristic feature. Obesity is a frequent condition among COVID-19 in-hospital patients (29) , present in up to 42% of those admitted to the hospital (30), but its influence in the prognosis has not been well described yet. However, the experience with other virus like H 1 N 1 influenza suggest that patients with obesity (31), even of young age, may evolve toward severe alveolitis with respiratory failure and death (32) . Therefore, this is not a minor finding and warrants future analysis and research. By late 2019, six coronavirus species have been described to cause human disease. Four RT-PCR of lower respiratory tract samples allowed sequencing the genome of a novel RNA-virus with 79.6 % of similarities with SARS-CoV, hence named SARS-CoV2 (7, 8) . Person-toperson transmission was rapidly described (9) . The SARS-CoV2 presents a spike protein to facilitate get into target cells. It links to ACE2 and is internalized after priming by the transmembrane protease, serine 2 (TMPRSS2) (7,10-12) (Figure 3) . ACE2 membrane-bound is part of a 3-enzymes system to convert angiotensin II to angiotensin-(1-7), with oppose properties to angiotensin II in order to balance human body ( Figure 3A) . ACE2 is considerable similar to ACE, which converts angiotensin-I to angiotensin-II (28, 33) , and this second, nor ACE2, is the target of ACE inhibitors. ACE2 is 2% in a soluble form -not valid for SARS-CoV2 binding-, after cleavage by a desintegrin and metalloprotease 17 (ADAM17). Angiotensin I upregulates ADAM17, thus increasing soluble ACE2 levels (13,14) ( Figure 3B) . Furthermore, ADAM17 also mediates the release of membrane bound precursors of pro-inflammatory cytokines (TNFα, IFN-γ, and IL-4) into the circulation. These cytokines, downregulate ACE2 cell surface expression reducing SARS-CoV2 capability of damage (15) (Figure 3C) . The hypothesis that RAAS-inhibitors might increase the susceptibility of patients taking them to COVID-19 pandemic and proposing its discontinuation were based in this pathophysiologic explanation (16) . On the other hand, Meng et al (18) found lower interleukin-6 and peak viral load in peripheral blood, and increased CD3 and CD8 T cells in patients with hypertension treated with RAAS-inhibitors. Despite this contradictory evidence, the most recent clinical data suggest that the upregulation of inflammatory cytokines by angiotensin-II, harmful to the outcomes of COVID-19 patients, can be decreased thanks to the reduced formation of angiotensin-II caused by RAAS-inhibitors, thus explaining the better clinical outcomes detected by leading-edge research groups (18, 26, 30) . The recommendation of discontinuation from RAAS-inhibitors was initially accepted by part of the medical community as a prophylactic measurement aiming to potentially reduce the risk of a severe respiratory disease. However, in this discussion one important issue was forgotten; loss-of-function experiments using ACE2 knockout mice have demonstrated increased susceptibility to myocardial infarction, hypertension and myocardial hypertrophy, microvascular complications, inflammation, fibrosis, diastolic and systolic dysfunction and oxidative stress (19) . Translated into humans, avoiding these drugs, where indicated, may increase major cardiovascular events causing more damage than the potential increased susceptibility to SARS-CoV2. Therefore, in view of the overwhelming evidence of mortality reduction in cardiovascular disease and the lack of impact found in our research, we believe that recommend RAASinhibitors should be maintained or even initiated in patients with new onset heart failure, hypertension, or myocardial infarction according to current guidelines as tolerated, irrespective of SARS-CoV2 disease outbreak. The frequently updated information on the disease suggests that, not only mortality due to COVID-19 has increased, but also other comorbidities are experiencing a rise in their mortality rates. Cardiovascular events are still the greatest cause of mortality in our society and inadequate handling of secondary prevention can have a catastrophic impact in the health status of the population (26, 29, 34) . However, as pointed out by Vaduganathan et al (26) , the effects on ACE2 should not be assumed to be uniform across RAAS-inhibitors or even in response to therapies within a given drug class. For this reason we need to remark that the current research only provided accurate evidence for Ramipril and not for other drugs of this group. The main limitations of the present study include its retrospective nature and the limited number of cases with confirmed COVID-19 infection. Detection of immunization should be undertaken as soon as confinement allows testing all patients in the trial in order to verify the real incidence of COVID-19 in this population, otherwise the real incidence of the disease remains unknown. Reporting this information in a near future is warranted but, still, reporting the impact of Ramipril on prognosis of symptomatic infection is clinically relevant. The relatively short length of the follow-up precludes from further conclusions regarding the long-term, but a continuous monitoring of patients at risk from the RASTAVI study will be performed. More than 10% of this high risk patients developed the COVID-19 and one-third of them died. Older patients with higher body mass index presented higher risk of infection and mortality, respectively. However, the use of Ramipril did not increase the risk of infection or impaired the prognosis. Hence, the use of RAAS-inhibitors during COVID-19 pandemic seems safe. Coronaviruses as the cause of respiratory infections Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China Identification of a novel coronavirus in patients with severe acute respiratory syndrome Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia N Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet A Novel Coronavirus from Patients with Pneumonia in China A pneumonia outbreak associated with a new coronavirus of probable bat origin Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers Angiotensin Converting Enzyme 2: A Double-Edged Sword Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19 Angiotensin-converting enzyme 2 protects from severe acute lung failure Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Renin-Angiotensin System Inhibition Following Transcatheter Aortic Valve Replacement Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study World Health Organization. Coronavirus disease 2019: situation report -76 Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Obesity and its Implications for COVID-19 Mortality COVID-19 and endocrine diseases. A statement from the SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?